Alexion Pharmaceuticals Inc. paused enrollment in a late-stage study testing the company’s rare blood-disorder drug in adults with severe Covid-19 requiring mechanical ventilation.

Supernus Pharmaceuticals Inc.’s experimental drug for attention deficit hyperactivity disorder (ADHD) met the main goal of a late-stage study in adults.

Ridgeback Biotherapeutics LP’s Ebanga is the first FDA-approved, single-injection Ebola treatment which is available in a lyophilized form.

The European Commission approved Aimmune Therapeutics Inc.’s Palforzia for the treatment of peanut allergy.

The U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices voted to recommend the use of Moderna Inc.’s Covid-19 vaccine on people 18 years of age and older.

The U.S. Food and Drug Administration approved GlaxoSmithKline plc’s Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis who are receiving standard therapy.

German biotech firm CureVac enrolled the first participant for a Phase 2b/3 clinical trial of the company’s Covid-19 vaccine candidate.

The U.S. Food and Drug Administration approved BioCryst Pharmaceuticals Inc.’s Orladeyo (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and young patients 12 years and older.

The U.S. Food and Drug Administration approved Genentech and Blueprint Medicines’ Gavreto (pralsetinib) as a treatment for adults and pediatric patients 12 and older who have been diagnosed with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC).

The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Oxlumo (lumasiran) for primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in children and adults.